DTC Stock Overview Develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Defence Therapeutics Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Defence Therapeutics Historical stock prices Current Share Price CA$0.65 52 Week High CA$2.32 52 Week Low CA$0.48 Beta 1.18 1 Month Change 25.00% 3 Month Change 6.56% 1 Year Change -68.14% 3 Year Change -87.00% 5 Year Change n/a Change since IPO -74.61%
Recent News & Updates Defence Therapeutics Inc. announced that it expects to receive CAD 4.2 million in funding Jan 01
Defence Therapeutics Inc Announces Executive Changes Nov 27 Defence Therapeutics Inc. announced that it expects to receive CAD 1.57 million in funding Nov 15
New major risk - Financial position Nov 15
Defence Therapeutics Inc., Annual General Meeting, Dec 12, 2024 Oct 22 Defence Therapeutics Inc. announced that it expects to receive CAD 3 million in funding Sep 27
See more updates Defence Therapeutics Inc. announced that it expects to receive CAD 4.2 million in funding Jan 01
Defence Therapeutics Inc Announces Executive Changes Nov 27 Defence Therapeutics Inc. announced that it expects to receive CAD 1.57 million in funding Nov 15
New major risk - Financial position Nov 15
Defence Therapeutics Inc., Annual General Meeting, Dec 12, 2024 Oct 22 Defence Therapeutics Inc. announced that it expects to receive CAD 3 million in funding Sep 27
Less than half of directors are independent Sep 11
New minor risk - Shareholder dilution Sep 05
Defence Therapeutics IncInvestigates the Application of the Accum Hydrogel Technology to Deliver GLP-1 in Order to Increase the Treatment Efficacy of Diabetes and Weight Loss Aug 21
Defence Therapeutics Inc. Announces Publication of A Peer-Reviewed Study on the Anticancer Properties of Its Unconjugated AccuTOX Jun 08
New major risk - Financial position Jun 02
Defence Therapeutics Inc. Tests a New Formulation of its ACCUM-002TM Dimer CDCA-SV40 Commonly Named AccuTOX® Jan 10
Defence Therapeutics Inc. Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with Accutox Dec 12
New minor risk - Share price stability Nov 17
Chief Technical Science Officer exercised options to buy CA$144k worth of stock. Oct 29
Defence Therapeutics Inc. Announces the Discovery of a Novel Function for Its Lead Antigen Injectable Drug AccuTOX Oct 26
Defence Therapeutics Inc. Announces Novel Accutox(Tm) Continues Toprise on Results Against Cancer Oct 19
Corporate Secretary exercised options to buy CA$145k worth of stock. Oct 13
Defence Therapeutics Inc. Announces Peer-Reviewed Publication of its Preclinical Data on Accum as Anti-Cancer Molecule in Journal of Cancer Science Oct 11
Defence Therapeutics Inc., Annual General Meeting, Dec 07, 2023 Oct 07
Defence Therapeutics Inc. Announces Accum-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines Sep 26
Defence Therapeutics Inc. Announces Reach the Final Stages of Its AccuTOX^TM Chemistry, Manufacturing and Controls Jun 16
Defence Therapeutics Inc. Begins Testing Its Arm Vaccine Against Pancreatic Cancer Jun 08
Defence Therapeutics Inc. Announces Successful Completion of Pre-Clinical Study Evaluating the Therapeutic Potency of Second-Generation Arm Vaccine Targeting Solid Tumoma May 25
Defence Therapeutics Inc. Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors Feb 04
Defence Therapeutics Inc. Announces Start of Its GLP Studies on A New Intranasal Accutoxtm Formulation Feb 02
Defence Therapeutics Inc. Announces Melanoma Targeted Vaccine A1- Reprogrammed MSC (ARM) Cell Potency Validated Jan 26
Defence Therapeutics Inc. Announces the Advancement in the Development of its Accum -mRNA Vaccine Program Jan 11
Defence Therapeutics Inc. Completes Pre-Clinical Study Using Its Intranasal Formulation of AccuTOXTM Dec 22
Defence Therapeutics Inc. Appoints Kwin Grauer to Its Board of Directors Dec 10
Defence Positioned to Begin Its Anti-Cancer AccuTOX(TM) Phase I Trial with Successful Completion of GLP Studies Dec 07
Defence Therapeutics Inc.'s Successfull Study on the AccuVAC- PT007 Vaccine Targeting Cervical Cancer Nov 24 Defence Therapeutics Inc. announced that it has received CAD 2.355 million in funding Nov 18
Defence Therapeutics Inc. announced that it has received CAD 2.335 million in funding Nov 17
High number of new and inexperienced directors Nov 16
Defence Therapeutics Inc. Initiates Lung Cance Treatment Program with Its Novel AccuTOX(TM) Formulation Via Intranasal Oct 13
Defence Therapeutics Inc., Annual General Meeting, Dec 08, 2022 Oct 07
Defence Therapeutics Inc. Reports Defence's Novel Vaccine Candidate Triggers A Potent Anti-Tumoral Response Capable of Curing Animals with Pre-Established Lymphoma Sep 22
Defence Therapeutics Inc. Reports the Development of A Novel Anti-Cancer Cellular Vaccine by Reprogramming the Unconventional Suppressive Mesenchymal Stromal Cells Aug 18
Defence Therapeutics Inc. to Report the Discovery of Novel DNA Damaging Function Triggered by One of Its Lead Compounds AccuTOXTM Aug 02
Defence Reports Effective Control of Cervical Cancer Growth in Response to Its AccuVAC-PT007 Therapeutic Vaccination Jun 28
Defence Therapeutics Inc.'s Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer May 19
High number of new and inexperienced directors Apr 27
Defence Therapeutics Inc. Announces the Development of AccuVAC-PT009 Jan 28
Defence Therapeutics Inc. Begins Ind-Enabling Testing of its Accutox Lead Compound Against Breast Cancer Jan 12
Defence Therapeutics Inc. to Finalize Its Objectives to Initiate A Phase I Trial Against Breast Cancer Oct 01
Defence Therapeutics Inc Announces Development Program to Engineer New HPV Vaccine Initiated Sep 09
We're Hopeful That Defence Therapeutics (CSE:DTC) Will Use Its Cash Wisely Sep 08
Defence Therapeutics Selects the Best 8 Accum Variants to Optimize Its ADC Therapeutic Aug 19
Defence Therapeutics Inc. Announces Major Breakthrough Advances in its Pre-Clinical Research Program on its Accutox Molecules as Potent Anti-Cancer Agents Jun 23
Defence Therapeutics Inc. Advances in Preclinical Testing of Its Infectious Disease Vaccine Program Jun 01 Shareholder Returns DTC CA Biotechs CA Market 7D 1.6% -0.4% -1.0% 1Y -68.1% 11.3% 16.9%
See full shareholder returns
Return vs Market: DTC underperformed the Canadian Market which returned 16.1% over the past year.
Price Volatility Is DTC's price volatile compared to industry and market? DTC volatility DTC Average Weekly Movement 10.9% Biotechs Industry Average Movement 13.0% Market Average Movement 8.3% 10% most volatile stocks in CA Market 18.2% 10% least volatile stocks in CA Market 2.9%
Stable Share Price: DTC has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: DTC's weekly volatility (11%) has been stable over the past year.
About the Company Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. It also offers Accuvac for dendritic cell cancer vaccines; a protein-based vaccine formulation against COVID and infectious diseases; and cervical cancer vaccine.
Show more Defence Therapeutics Inc. Fundamentals Summary How do Defence Therapeutics's earnings and revenue compare to its market cap? DTC fundamental statistics Market cap CA$28.66m Earnings (TTM ) -CA$11.60m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) DTC income statement (TTM ) Revenue CA$0 Cost of Revenue CA$0 Gross Profit CA$0 Other Expenses CA$11.60m Earnings -CA$11.60m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.24 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -44.0%
How did DTC perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/15 06:44 End of Day Share Price 2025/01/15 00:00 Earnings 2024/09/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Defence Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
